<DOC>
	<DOCNO>NCT02678455</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity recombinant live attenuate tetravalent dengue virus vaccine admixture TV005 ( TetraVax-DV T005 ) healthy adult , adolescent , child Dhaka , Bangladesh .</brief_summary>
	<brief_title>Safety Immunogenicity Dengue Virus Vaccine TV005 ( TetraVax-DV TV005 ) Healthy Adults , Adolescents , Children Dhaka , Bangladesh</brief_title>
	<detailed_description>Dengue virus ( DENV ) lead arboviral infection globally , 2 billion people risk infection worldwide . The first dengue fever outbreak Bangladesh occur 2000 , since , dengue fever continue presence throughout Bangladesh . This study evaluate safety immunogenicity recombinant live attenuate tetravalent dengue virus vaccine admixture TV005 ( TetraVax-DV T005 ) healthy adult , adolescent , child Dhaka , Bangladesh . The study enroll four cohort participant : adult , adolescent , child , young child . Study researcher evaluate study data cohort enrol subsequent cohort . Participants randomly assign receive either TV005 vaccine placebo study entry ( Day 0 ) . Additional study visit occur Days 7 , 14 , 28 , 56 , 180 , 360 , 720 , 1080 . Study visit include blood collection , physical examination , clinical assessment . Participants record monitor temperature symptom Day 14 . Study staff contact participant daily Day 14 ; Day 14 , study staff contact participant weekly ( Day 180 , monthly ) throughout study follow-up health monitoring .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female ( nonpregnant lactating ) age 12 month 50 year time enrollment study . Reside Mirpur Wards 2 , 3 , 5 ( Wards within Mirpur designate PI need reach enrollment target ) time screen . Study participant and/or parents/guardians/legally acceptable authorize representative ( LARs ) Investigator believe comply requirement protocol ( e.g. , return followup visit ) . Good general health determine physical examination , laboratory screening , review medical history . If participant great equal 18 year age , informed consent form sign date study participant ( independent witness require local regulation ) . If study participant minor , assent form ( participant age 1117 year ) inform consent form sign dated participant 's properly identify parent ( ) legally acceptable representative . If participant less 11 year age , participant 's parent ( ) legally acceptable representative consent sign consent form minor participant . If participant female , must pregnant plan become pregnant 28 day post vaccination . Female participant age 18 enrol , yet reach menarche . Females 18 year age old , must properly use method pregnancy prevention know highly effective per PI . Reliable method contraception include : hormonal birth control , condom spermicide , diaphragm spermicide , surgical sterilization , intrauterine device , abstinence ( great equal 6 month since last sexual encounter ) . For female study participant 18 year age old pregnancy test occur screen vaccination must negative pregnancy test prior vaccination . Additionally , receive counsel importance effective contraception 30 day prior vaccination continue Day 28 . Counselling occur screen visit , clinic visit day Day 28 . Female participant 18 year age old subject pregnancy test Study Day 28 56 visit . If female participant age 18 yet reach menarche prior enrollment , reach menarche study , continue enrol followedup entire three year followup period . Pregnant lactate female female planning become pregnant within 28 day receive investigational product planning discontinue abstinence contraceptive precaution within 28 day receive investigational product . Menstruating female age 18 exclude enrol . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal , autoimmune , hematologic , endocrine disease functional defect , determine history , physical examination , screen test . History neurological , psychiatric , behavioural disorder seizure , exception single febrile seizure childhood . Selfreported suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( prednisone equivalent , great equal 0.5 mg/kg/day 20 mg/day , 2 consecutive week within past 3 month ) . Inhaled topical steroid allow . Having heightforage zscore ( HAZ ) weightforage zscore ( WAZ ) less equal 3 child age two . Severe malnutrition observe study physician study participant age 2 year old old . Hepatitis C virus ( HCV ) infection screen confirmatory assay ( screen adult adolescent ) , hepatitis B virus ( HBV ) infection , hepatitis B surface antigen ( HBsAg ) screening ( participant ) , unwilling allow HCV ( adults adolescent ) HBV test . Screening laboratory value Grade 1 absolute neutrophil count ( ANC ) , alanine transaminase ( ALT ) , platelet count , define protocol . For child 5 year age , screen laboratory value Grade 1 Haemoglobin . History allergic reaction likely exacerbated component vaccine ; history severe allergic reaction anaphylaxis . Current alcohol abuse drug addiction might interfere ability comply trial procedure . Any condition opinion Investigator would jeopardize safety right participant participate trial would render participant unable comply protocol . Planned administration vaccine 30 day prior receipt study vaccine end 30 day ; exception standard infant child Expanded Program Immunization ( EPI ) inactivate vaccine inactivate influenza vaccine inactivate rabies vaccine ( without administration immunoglobulin ) administer adults child . Use investigational nonregistered drug vaccine study vaccine within 30 day precede receipt study vaccine/placebo plan use time study period history receive investigational dengue vaccine previous time . Current participation clinical investigational study . Administration immunoglobulins and/or blood product within 90 day precede dose plan administration time study period , might interfere assessment immune response . A plan anticipate move location prohibit full participation trial three year duration . Potential adult volunteer parent potential child volunteer , easy access fix mobile telephone . Any participant resides household individual previously enrol old age cohort study . Only one participant household enrol . Any participant identify site employee Investigator study clinic , direct involvement propose study study direction Investigator study clinic , well immediate family member ( husband , wife child , adopt natural ) clinic employee Investigator . Elimination Criteria During Study : The follow criterion check visit subsequent first visit . If become applicable study , require withdrawal participant study may determine participant 's evaluability perprotocol ( PP ) analysis . The participant continue evaluate safety purpose regularly schedule visit . See protocol definition study cohort evaluate . Use investigational nonregistered product ( drug vaccine ) study vaccine/placebo study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug study period . For corticosteroid , mean prednisone , equivalent , great equal 0.5 mg/kg/day . Inhaled topical steroid allow . Administration license vaccine period start 30 day dose vaccine/placebo end 30 day , exception standard infant childhood EPI `` inactivate '' vaccination . Administration immunoglobulins and/or blood product study period . Pregnancy within 28 day investigational product administration .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dengue Virus</keyword>
</DOC>